窦卵泡计数与抗苗勒管激素按POSEIDON标准分类低预后女性的一致性研究
该研究纳入巴西、土耳其和越南三个生育中心2015至2017年间9484例首次IVF/ICSI的不孕女性,比较窦卵泡计数(AFC)与抗苗勒管激素(AMH)按POSEIDON标准分类低预后患者的一致性。结果显示总体一致性强(kappa=0.802),73.8%患者被分入相同组别,但约26%患者两种标志物分类不一致;两者预测获卵数的准确性相当。
要点
- AFC与AMH按POSEIDON标准分类的一致性强度高(kappa=0.802)。
- 73.8%患者使用两种标志物被分入相同POSEIDON组,约26%分类不一致。
- 预测低获卵数(<4)的最佳AFC切点为5、AMH为1.27 ng/ml。
核心结论
- AFC与AMH在按POSEIDON标准分类低预后患者时一致性强,任一种均可用于分类。
- 但四分之一的女性在同时使用两种标志物时会出现分类不一致。
研究设计与样本
- 基于人群的队列研究,纳入巴西、土耳其和越南三个生育中心2015至2017年间9484例连续患者。
- 研究对象为22至46岁、首次接受标准卵巢刺激IVF/ICSI且基线同时评估了AFC和AMH的不孕女性。
- AFC经早期卵泡期二维经阴道超声测定,AMH采用改良Beckman Coulter第二代酶联免疫吸附 assay 测定。
- 采用Cohen kappa统计量计算AFC与AMH分类的一致性,并用法logistic回归分析卵巢标志物与获卵数的关联。
主要发现
- 按POSEIDON分组分类的总体一致性强度高(kappa=0.802;95%CI:0.792-0.811)。
- 73.8%的个体使用两种标志物被分入相同组别,不一致率约26%,且以AFC或AMH为主标准时不一致率无差异。
- 卵巢标志物与获卵数之间存在显著回归方程(P<0.0001)。
- 预测低获卵数(<4)的最佳AFC切点为5(敏感度0.61,特异度0.81,AUC 0.791),AMH切点为1.27 ng/ml(敏感度0.66,特异度0.72,AUC 0.751)。
- 预测次优获卵数(4-9)的AFC切点为12(敏感度0.74,特异度0.76,AUC 0.81),AMH切点为2.97 ng/ml(敏感度0.69,特异度0.66,AUC 0.80)。
关键数值与推荐
- POSEIDON标准中AFC和AMH的拟议阈值分别为5和1.2 ng/ml,来源于已发表文献。
- 本研究中预测低获卵数(<4)的最佳AFC和AMH切点分别为5和1.27 ng/ml。
- 预测次优获卵数(4-9)的AFC和AMH切点分别为12和2.97 ng/ml。
- AMH数据须以检测方法特异性方式解读。
临床怎么用
- 临床可按POSEIDON标准使用AFC或AMH对低预后患者进行分类,两者分类一致性可接受。
- 两种标志物预测获卵数的准确性相当,支持在每日临床实践中使用其拟议阈值进行患者分类。
- POSEIDON阈值预测低获卵数的敏感度较低,临床医生应选择最能反映本机构临床情况的标志物。
局限性
- 研究依赖二维经阴道超声量化AFC和手动Gen II assay测定AMH。
- AMH数据必须以检测方法特异性方式解读。
- 各中心治疗方案存在差异,可能影响患者分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the agreement between antral follicle count (AFC) and anti-Müllerian hormone (AMH) levels when used to patient classification according to the Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria? SUMMARY ANSWER: Our study indicates a strong agreement between the AFC and the AMH levels in classifying POSEIDON patients; thus, either can be used for this purpose, although one in four women will have discordant values when both biomarkers are used. WHAT IS KNOWN ALREADY: According to the POSEIDON criteria, both AFC and AMH may be used to classify low-prognosis patients. Proposed AFC and AMH thresholds of 5 and 1.2 ng/ml, respectively, have their basis in published literature; however, no study has yet determined the reproducibility of patient classification in comparing one biomarker with the other, nor have their thresholds ever been validated within this patient population. STUDY DESIGN, SIZE, DURATION: A population-based cohort study involving 9484 consecutive patients treated in three fertility clinics in Brazil, Turkey and Vietnam between 2015 and 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants were infertile women between 22 and 46 years old in their first in vitro fertilization/intracytoplasmic sperm injection cycle of standard ovarian stimulation with exogenous gonadotropins whose baseline ovarian reserves had been assessed by both AFC and AMH. Details of pre- and post-treatment findings were input into a coded research file. Two indicators of interest were created to classify patients according to the POSEIDON criteria based upon AFC and AMH values. Patients who did not fit any of the four POSEIDON groups were classified as non-POSEIDON. AFC was determined in the early follicular phase using two-dimensional (2D) transvaginal ultrasonography, whereas AMH values were based on the modified Beckman Coulter generation II enzyme-linked immunosorbent assay. Agreement rates were computed between AFC and AMH to classify patients using Cohen's kappa statistics. Logistic regression analyzes were carried out to examine the association between ovarian markers and low (<4) and suboptimal (4-9) oocyte yield. MAIN RESULTS AND THE ROLE OF CHANCE: The degree of agreement in classifying patients according to POSEIDON groups was strong overall (kappa = 0.802; 95% CI: 0.792-0.811). A total of 73.8% of individuals were classified under the same group using both biomarkers. The disagreement rates were ∼26% and did not diverge when AFC or AMH was used as the primary biomarker criterion. Significant regression equations were found between ovarian markers and oocyte yield (P < 0.0001). For low oocyte yield, the optimal AFC and AMH cutoff values were 5 and 1.27 ng/ml with sensitivities of 0.61 and 0.66, specificities of 0.81 and 0.72, and AUC receiver operating characteristics of 0.791 and 0.751, respectively. For suboptimal oocyte yield respective AFC and AMH cutoffs were 12 and 2.97 ng/ml with sensitivities of 0.74 and 0.69, specificities of 0.76 and 0.66 and AUCs of 0.81 and 0.80. LIMITATIONS, REASONS FOR CAUTION: Our study relied on 2D transvaginal sonography to quantify the AFC and manual Gen II assay for AMH determination and classification of patients. AMH data must be interpreted in an assay-specific manner. Treatment protocols varied across centers potentially affecting patient classification. WIDER IMPLICATIONS OF THE FINDINGS: Three of four patients will be classified the same using either AFC or AMH values. Both biomarkers provide acceptable and equivalent accuracy in predicting oocyte yield further supporting their use and proposed thresholds in daily clinical practice for patient classification according to the POSEIDON criteria. However, the sensitivity of POSEIDON thresholds in predicting low oocyte yield is low. Clinicians should adopt the biomarker that may best reflect their clinical setting. STUDY FUNDING/COMPETING INTEREST(S): Unrestricted investigator-sponsored study grant (MS200059_0013) from Merck KGaA, Darmstadt, Germany. The funder had no role in study design, data collection, analysis, decision to publish or manuscript preparation. S.C.E. declares receipt of unrestricted research grants from Merck and lecture fees from Merck and Med.E.A. H.Y. declares receipt of payment for lectures from Merck and Ferring. L.N.V. receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD) and Ferring and research grants from MSD and Ferring. T.M.H. received speaker fees and conferences from Merck, MSD and Ferring. The remaining authors have nothing to disclose. TRIAL REGISTRATION NUMBER: not applicable.
引用
- Esteves SC, Yarali H, Vuong LN, et al. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. Hum Reprod. 2021. PMID: 33822057. doi:10.1093/humrep/deab056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。